Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Doximity (DOCS) Total Current Liabilities (2021 - 2025)

Doximity (DOCS) has disclosed Total Current Liabilities for 5 consecutive years, with $149.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Total Current Liabilities rose 29.31% to $149.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $149.8 million, a 29.31% increase, with the full-year FY2025 number at $156.3 million, up 6.12% from a year prior.
  • Total Current Liabilities was $149.8 million for Q4 2025 at Doximity, up from $140.3 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $159.9 million in Q2 2025 to a low of $91.7 million in Q4 2021.
  • A 5-year average of $124.1 million and a median of $122.0 million in 2022 define the central range for Total Current Liabilities.
  • Peak YoY movement for Total Current Liabilities: decreased 1.06% in 2023, then rose 29.31% in 2025.
  • Doximity's Total Current Liabilities stood at $91.7 million in 2021, then rose by 15.45% to $105.9 million in 2022, then fell by 1.06% to $104.8 million in 2023, then rose by 10.61% to $115.9 million in 2024, then increased by 29.31% to $149.8 million in 2025.
  • Per Business Quant, the three most recent readings for DOCS's Total Current Liabilities are $149.8 million (Q4 2025), $140.3 million (Q3 2025), and $159.9 million (Q2 2025).